Oct. 12, 2012 | Vol. 11 No. 201 | Full Issue in PDF Format
View the entire issue.
Rep. Edward Markey (D-Mass.) continues to push the FDA for answers about how it will respond to a compounding pharmacy linked to 14 deaths.
GlaxoSmithKline (GSK) will soon allow researchers access to detailed anonymized patient-level clinical data for approved drugs as well as dropped investigational products.
A new study finds that one-third of drugs approved in Canada using Health Canada’s priority approval process eventually develop safety problems.
Clinical trial investigators in the EU must post their trial results to a publicly available database within six months for pediatric trials and within a year for all other trials, according to a European Commission (EC) guideline.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.